Formulary guidance and transparency from P&T to point of care


Reality Check on Multiple Sclerosis

Market access for multiple sclerosis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about half of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In October 2019, the FDA approved Biogen Inc. and Alkermes plc’s Vumerity (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsingremitting disease and active secondary progressive disease
  • Key Findings: Contracting is prevalent among the interferons, where formulary preference drives choice. The orals are all different molecules. Contracting is expected to occur for these drugs but not to compete against the other brands

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.